ABSTRACT
Influenza virus infections affect millions of people annually. Current available vaccines provide varying rates of protection. There is a knowledge gap on how the nasal microbiota, particularly established pneumococcal colonization, shapes the response to influenza vaccination. In this study, we inoculated healthy adults with live S. pneumoniae and vaccinated them three days later with either TIV or LAIV. Vaccine-induced immune responses were assessed in nose, blood and lung. Nasal pneumococcal colonization had no impact upon TIV-induced antibody responses to influenza, which manifested in all compartments. However, pre-existing pneumococcal colonization dampened LAIV-mediated mucosal antibody responses, primarily IgA in the nose and IgG in the lung. Pulmonary influenza-specific cellular responses were more apparent in the LAIV group compared to either TIV or an unvaccinated group. These results indicate that TIV and LAIV elicit differential immunity to adults and that LAIV immunogenicity is diminished by the nasal presence of S. pneumoniae. This important confounder should be considered when assessing LAIV efficacy.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03502291
Funding Statement
This work was funded by grants from BMGF (OPP1117728) awarded to D.Ferreira and MRC grants (MR/M011569/1) awarded to S.Gordon. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Flow cytometric acquisition was performed on a BD LSRII funded by WelIcome Trust Multi-User Equipment grant (104936/Z/14/Z). Also, the authors thank the Data Monitoring and Safety Committee (Brian Faragher, Christopher Green, and Robert C. Read).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw RNA-sequencing data will be deposited in the GEO repository All datasets used and analysed during the current study will be available from the Liverpool school of Tropical Medicine online repository. This can be accessed via: http://archive.lstmed.ac.uk/.
